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Abstract The aging process is associated with loss of muscle
mass and strength and decline in physical functioning. The
term sarcopenia is primarily defined as low level of muscle
mass resulting from age-related muscle loss, but its definition
is often broadened to include the underlying cellular processes
involved in skeletal muscle loss as well as their clinical
manifestations. The underlying cellular changes involve
weakening of factors promoting muscle anabolism and
increased expression of inflammatory factors and other agents
which contribute to skeletal muscle catabolism. At the cellular
level, these molecular processes are manifested in a loss of
muscle fiber cross-sectional area, loss of innervation, and
adaptive changes in the proportions of slow and fast motor
units in muscle tissue. Ultimately, these alterations translate to
bulk changes in muscle mass, strength, and function which
lead to reduced physical performance, disability, increased
risk of fall-related injury, and, often, frailty. In this review, we
summarize current understanding of the mechanisms under-
lying sarcopenia and age-related changes in muscle tissue
morphology and function. We also discuss the resulting long-
term outcomes in terms of loss of function, which causes
increased risk of musculoskeletal injuries and other morbid-
ities, leading to frailty and loss of independence.
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Introduction
Skeletal muscle contractions power human body move-
ments and are essential to maintaining stability. Skeletal
muscle tissue accounts for almost half of the human body
mass and, in addition to its power generation role, is a
crucial factor in maintaining homeostasis of glucose
metabolism. Given its central role in human mobility and
metabolic function, any deterioration in the contractile,
material, and metabolic properties of skeletal muscle has an
extremely important effect on human health. Because the
population in the USA aged 65 and over is expected to
approximately double over the next 15 years [1], age-
related losses in skeletal muscle mass and function present
an extremely important current and future public health
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issue. Loss of mobility, one of the major consequences of
age-related skeletal muscle deterioration, is one of the
primary determinants of the need for nursing home care, a
public health cost which the US Health Care Finance
Administration predicts may exceed 183 million dollars by
2010 [2]. The term coined by I.H. Rosenberg, which is
widely used to describe skeletal muscle loss, is sarcopenia,
from the Greek roots sarx (flesh) and penia (loss).
Although this term is clinically applied to denote loss of
muscle mass, it is often used to describe both a set of
cellular processes (denervation, mitochondrial dysfunction,
inflammatory and hormonal changes) and a set of outcomes
such as decreased muscle strength, decreased mobility and
function, increased fatigue, increased risk of metabolic
disorders, and increased risk of falls and skeletal fractures.
In this review, we (1) summarize current understanding of
the mechanisms which underlie sarcopenia, (2) relate this
information to age-related changes in muscle tissue mor-
phology and function, and (3) describe the resulting long-
term outcomes in terms of loss of function, which cause
increased risk of musculoskeletal injuries and other morbid-
ities, finally leading to frailty and loss of independence.
Muscle fiber structure and the neuromuscular junction
This section is derived from a number of excellent reviews
of muscle cell structure and function [3, 4]. All of the
body’s skeletal muscles are composed of multinucleated
cells called fibers. Each fiber incorporates the contractile
proteins myosin and actin, along with numerous other
regulatory proteins, which are organized into thick and thin
filaments, respectively. The myosin and actin filaments are
arranged in periodic bands within structures called sarco-
meres, and a repeated sequence of sarcomeres form tube-
like structures called myofibrils. Each muscle fiber contains
a large number of parallel myofibrils, and the force
generated by the muscle fiber is proportional to the number
of myofibrils it contains. Muscles are innervated by motor
neurons. In the case of small muscles used for fine motor
control, motor neurons may innervate only a few small
fibers. In larger muscles, a fiber is innervated by a single
branch of a motor neuron, and the motor neuron innervates
many muscle fibers. The combination of a single motor
neuron and the muscle fibers innervated by its branches is
called a motor unit. The hierarchic organization of muscle
tissue is diagrammed in Fig. 1.
A skeletal muscle motor unit is activated when a signal
is generated in the motor cortex of the brain, traveling
though the spinal cord, and is transmitted as an action
potential through the motor neurons to each fiber in the
motor unit, resulting in a simultaneous contraction of the
fibers. When the nerve impulse reaches the junction
between the motor neuron branch and the fiber, acetylcho-
line is released from the axon end of the neuron. A wave of
electrical changes are produced in the muscle cell when the
acetylcholine binds to receptors on the fiber cell surface,
causing release of calcium from the sarcoplasmic reticulum,
which activates the contractile machinery to generate
power.
The power generated in a muscle contraction is provided
by the interaction of the actin and myosin components
within the sarcomere. In the broadest terms, this occurs
when the myosin component attaches to the actin frame-
work. Following a sequence of chemical transformations
via actin-induced breakdown of adenosine triphosphate
(ATP), free energy is released to generate both force
production and movement of actin within the sarcomere,
thereby causing the whole muscle to generate force and
movement. Several reviews describing this process are
provided in the following references [5–12].
Motor units are differentiated into three main types
based on the specific type of myosin expressed in the
fibers. Slow motor units contain the smallest number of
fibers and consist of type 1 myosin, which transduces
energy at a relatively slow rate. Thus, these fibers/motor
units contract with relatively slow velocity. Type I fibers in
slow motor units are especially rich in mitochondria and
myoglobin, which make them reddish in color and which
allow for a high capacity for sustained delivery of ATP
from oxidative metabolism of triglycerides and carbohy-
drate. The oxidative ATP synthesis process characteristic of
type I fibers is relatively slow to ramp up and can be
sustained for long periods of time, making these motors
units well-suited for sustained aerobic exercise such as
distance running. Additionally, the low contraction velocity
means that these slow motor units are also heavily recruited
in precise finite motor activities and in opposing gravity.
Fast fatigable motor units generate more force and have
higher velocities than slow motor units, both because they
have the highest number of fibers and because the
individual fibers have the largest cross-sectional area
(CSA) and the highest contractile velocity. These motor
units express type IIx myosin, which transduces energy at a
faster rate than type I myosin. These fibers are relatively
poor in mitochondria, and the primary source of ATP is
through glycolysis of glycogen, which can provide consid-
erable energy over a relatively short time period. Fast
fatigable motor units are typically recruited during activities
such as weightlifting or sprinting, which require maximal
power generation. In addition, there is a third type of motor
unit, the fast fatigue-resistant motor unit, which transduces
energy at a rate which is intermediate between slow and fast
fatigable motor units. Fast fatigue-resistant motor units
contain type IIa myosin and are intermediate in CSA
between type I and type IIx and are also intermediate in
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terms of the number of fibers and in velocity of contraction.
Contractile force, normalized by CSA, is similar across
fiber types, but the maximum power, normalized for fiber
CSA, of the fast fatigable motor units is at least four times
greater due to the higher contractile velocity compared to
the slow type I motor units.
Age-related changes in muscle contractile properties
The term “sarcopenia” has been employed to describe the
loss of muscle tissue that occurs over a lifetime and is also
commonly used to describe its clinical manifestation as
well. Age-associated processes bring about changes in the
mass, composition, contractile properties, and material
properties of muscle tissue, as well as in the function of
tendons. These changes translate to alterations in muscle
power, strength, and function, leading to reduced physical
performance, disability, increased risk of fall-related injury,
and, often, frailty. This section will provide a brief review
of some of the age-related changes that affect the contractile
and material properties of muscle as well as the function of
tendons.
Age-related changes in muscle morphology
The age-related loss of muscle mass results from loss of
both slow and fast motor units, with an accelerated loss of
fast motor units. In addition to the loss of fast motor units,
there appears to be fiber atrophy, or loss of CSA, of type II
fast glycolytic fibers [13, 14]. As motor units are lost via
denervation, an increased burden of work is transferred to
surviving motor units, and as a potential adaptive response,
remaining motor units recruit denervated fibers, changing
their fiber type to that of the motor unit. Thus, there is a net
conversion of type II fibers to type I fibers, as the type II
fibers are recruited into slow motor units (Fig. 2). As a
result, although there is relatively little change in the
average CSA of type I fibers, the percentage of the total
muscle cross-sectional area occupied by type I fibers tends
to increase with age, whereas not only are type II fibers lost
but the CSA and the aggregate power-generating capacity
of the remaining fibers also decrease dramatically. Finally,
while in young muscle tissue there is a mosaic-like
appearance corresponding to presence of both types of
fibers, in aged muscle, the recruitment of denervated fibers
by surviving motor units causes a clustering of similar fiber
types [13, 14].
The loss of both type I and accelerated loss of type II
fibers results in sharp age-related changes in muscle
function. The loss of fast motor units and the concomitant
loss of type II fibers result in loss in muscle power
necessary for actions such as rising from a chair, climbing
steps, or regaining posture after a perturbation of balance.
The extent of skeletal muscle power loss with age has been
confirmed by studies of cycle ergometry in which the cycle
velocity at maximal power was measured. In a study of
human volunteers ranging in age from 20 to 90 years,
Kostka et al. found that velocity at maximal power
decreased by roughly 18% between ages 20–29 and 50–
59 and by a further 20% between 60–69 and 80–89 [15]. In
addition to studies examining muscle power and contrac-
Fig. 1 Hierarchical depiction of skeletal muscle structure, depicting the skeletal muscle fibers within the muscle bundle, a motor unit branching
out to two muscle fibers and the detailed structure of myofibrils
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tion velocities, other studies have cross-sectionally exam-
ined age-related changes in strength, showing strength
declines as great as 30–35% [16]. These alterations in
strength have been linked primarily to declines in muscle
mass as well as reductions in power per unit area and force
per unit area, as nonmuscle tissue components replace lost
muscle fiber [17].
Another morphologic aspect of aging skeletal muscle is
the infiltration of muscle tissue components by lipid, which
can be contained within adipocytes as well as deposited
within muscle fiber. The aging process is thought to result
in increased frequency of adipocytes within muscle tissue.
As with precursor cells in bone marrow, liver, and kidney,
muscle satellite cells can express both adipocytic and a
myocytic phenotypes, and recent studies have reported that
expression of the adipocytic phenotype is increased with
age [18–21]. This process is still relatively poorly under-
stood in terms of its extent and spatial distribution. Another
well-known source of adiposity in muscle tissue is through
increased deposition of lipid within muscle fibers [22–28].
This type of lipid distribution, often referred to as intra-
myocellular lipid, may result from net buildup of lipid due
to reduced oxidative capacity of muscle fibers with aging
[22, 29].
Neurologic underpinnings of muscle atrophy
The correct functioning of motor neurons is essential to the
survival of muscle fibers. Age-related neurodegeneration
may contribute importantly to the effects of age on muscle
structure, including loss of muscle fibers, atrophy of muscle
fibers, and increased clustering of muscle fibers as
denervated fibers are recruited into viable motor units.
Multiple levels of the nervous system are affected by age,
including the motor cortex (beyond the scope of this
review), the spinal cord, peripheral neurons, and the
neuromuscular junction. Within the spinal cord, there is a
substantial decline in the number of alpha motor neurons,
and there may be a preferential loss in those motor neurons
supplying fast motor units. Other reports have noted age-
related losses in peripheral nerve fibers and alterations of
their myelin sheaths. Finally, age-related changes have been
noted in the neuromuscular junction, with reduced number
[30] but increased size of terminal areas and a reduction in
the number of synaptic vesicles [31]. Others have noted
increases in the amount of neurotransmitters released in
nerve impulses and increased sprouting and branching of
terminal axons, all of which may serve as an adaptive
mechanism underlying the ability of viable motor units to
recruit denervated muscle fibers [32].
Key factors in age-related changes in protein balance
Skeletal muscle is characterized by a dynamic balance
between the synthesis of protein from free amino acids in
the cellular milieu and the dissociation of muscle protein into
free amino acids. Maintenance of muscle mass requires that
the rate of synthesis be in balance with the rate of degradation;
over time, deficits can result in severe muscle loss. Aging is
associated with decreased expression of hormonal factors that
Fig. 2 Effect of age on the
motor unit, depicting, young,
aged, and aged sarcopenic
fibers. This drawing depicts the
pronounced denervation of type
II fibers and the recruitment of
type I fibers into surviving mo-
tor units in older subjects, with
impairment of recruitment in
sarcopenic subjects
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promote protein synthesis and increased expression of both
endocrine and inflammatory factors that contribute negatively
to protein balance by increasing protein degradation. Figure 3
summarizes the role of endocrine, inflammatory, and other
factors in protein synthesis.
IGF-1
Insulin-like growth factor 1 (IGF-1) is a well-known
promoter of protein synthesis in skeletal muscle. Skeletal
muscle fibers have a set of transmembrane receptors that
bind insulin and IGF-1 to regulate proliferation, differenti-
ation, and fusion of skeletal muscle precursor cells [33].
There are two primary sources of IGF-1. Mature IGF-1 is
produced systemically by the interaction of growth hor-
mone (GH) with the liver. The other source of IGF-1 is
within the skeletal muscle itself, with two primary variants
[34], including one which is produced in response to
physical activity and is referred to as mechano growth
factor and one which is similar to the mature IGF-1
produced within the liver [35, 36]. IGF-1 binds to receptors
on skeletal muscle cell surfaces and activates a complex
array of cell signaling pathways which are anabolic,
anticatabolic, and antiapoptotic [37]. This age-related
decline stems both from the decline of growth hormone,
which results in reduced liver IGF-1 production as well as a
reduction in the ability of skeletal muscle cells to produce
IGF-1 locally. Therefore, the age-related decline in IGF-1
production is linked to age-related reductions in protein
synthesis and muscle cell function. Finally, loss of IGF-1
may also compromise motor neuron function in aging. IGF-
1 overexpression in transgenic mice has been reported to
protect against age-related changes in the neuromuscular
junction [38], and in other reports IGF-1 was found to be
instrumental in transforming nerve action potential to the
release of calcium ion from the sarcoplasmic reticulum
[39].
Age-related changes in inflammatory factors
In chronic inflammatory diseases associated with muscle
atrophy, such as cancer cachexia and autoimmune disor-
ders, muscle cell protein degradation is accelerated, and
muscle protein synthesis appears to be diminished [40, 41].
The ubiquitin–proteasome pathway is the most important
mechanism for protein degradation in skeletal muscle cells.
This system involves a series of enzymatic steps in which
the degraded proteins are first targeted by an enzyme
system that binds the target protein to the polypeptide
ubiquitin. These ubiquitinized proteins are then transferred
to the proteasome complex and degraded into short peptides
and are finally recycled as free intracellular amino acids
[42]. This pathway is promoted by inflammatory cytokines
such as tumor necrosis factor alpha (TNF-α) and interleu-
kin 6 (IL-6), by hormones such as cortisol and angiotensin,
as well as by reactive oxygen species.
Increased expression of these inflammatory cytokines
also appears to be common in aging in skeletal muscle.
Fig. 3 Age effects on systemic
factors influencing synthesis and
degradation of skeletal muscle
proteins
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Comparison of skeletal muscle biopsies from younger and
older subjects showed increased expression of genes
upregulated by inflammatory factors [43]. Levels of
catabolism-inducing hormones such as cortisol have also
been shown to increase with age, and cortisol is linked to
increased expression of IL-6 and TNF-α. Increased TNF-α
expression is also known to stimulate muscle atrophy
through apoptosis. Apoptosis contributes to the loss of
myonuclei in skeletal muscle cells and could theoretically
result in the loss of complete fibers in sarcopenia [44].
Oxidative damage
Oxidative metabolism generates reactive oxygen species
(ROS), and these metabolic products are thought to
accumulate over time, altering and damaging cell compo-
nents, particularly mitochondria and DNA sequences [45].
Because mitochondria produce ROS, they are subject to
alterations in their structure and in their DNA. Alterations
to mtDNA are known to increase with age in skeletal
muscle, and the frequency of abnormal mitochondrial
regions is higher in those muscles which are strongly
affected by sarcopenia [45–47]. The role of mitochondrial
DNA alterations in age-related loss of skeletal muscle
function is under intense investigation, focusing on their
roles in causing skeletal muscle cell apoptosis and structural
abnormalities that affect metabolic function. Structural
alterations to mitochondria may affect the electron transport
chain, compromising respiration. Although the loss of
maximal oxygen consumption (VO2 max) with age has
been primarily attributed to loss of muscle mass and
reduced cardiac output, altered mitochondrial metabolism,
leading to poorer muscle cell respiration, may also be
involved.
Intrinsic changes to skeletal muscle
One potential mechanism for sarcopenia involves the loss
of muscle regenerative capacity due to loss in the number
and function of muscle satellite cells, which proliferate and
differentiate into skeletal muscle fibers. Some studies have
observed declines in the numbers of muscle satellite cells in
both rodents and humans [48], with others reporting that
this decline was larger in muscles containing primarily type
II fibers than in those containing type 1 fibers [49].
However, other studies have failed to observe a change in
satellite cell number with age, and others have even
reported slight increases [50]. There is some evidence that
failure of muscle tissue to regenerate may involve age-
related changes in the molecular regulators, called myo-
genic regulatory factors (MRF) of muscle satellite cell
proliferation and differentiation, rather than in the number
of satellite cells. In general, studies that have compared the
expression of MRFs such as myogenic determination factor
(myoD), myogenic regulatory factor 5, and myogenin in
rats have found that expression of these factors is decreased
in older compared to younger skeletal muscle [51]. Human
studies have shown impaired differentiation of myoblasts,
which has been associated with reduced or delayed
expression of these factors [52]. Another factor in the
behavior of muscle satellite cells is myostatin, which is
thought to suppress differentiation and proliferation of
myocytes by suppressing the expression of MRFs such as
myoD and myogenin [53]. While there is considerable
work which has demonstrated that myostatin suppression
may have therapeutic potential for combating muscle
wasting, the effect of age on myostatin expression is still
under active investigation. Some investigations using rat
models have found that myostatin mRNA levels have
remained constant with age [54], while others observed
age-related increases [55]. With respect to studies in human
models of muscle wasting, there is similar variance in
findings, with one cross-sectional study reporting no
change in myostatin expression in the vastus lateralis
muscle between young and older men [56], while a similar
study in women found a 56% increase in myostatin
expression in the vastus lateralis [57]. Thus, while
myostatin is an important target in combating muscle
wasting, the role of age-related changes in myostatin
expression is still a controversial subject.
Age-related changes in the stiffness
of the muscle–tendon system
When considering age-related losses in performance, it is
important to take into account that muscle and tendons act
as a unit. Human motion requires the transmission of
contractile forces generated in skeletal muscle tissue
through the tendons to the skeleton. Thus, age-related
alterations in mobility are not only a function of changing
skeletal muscle contractile properties but also of the
mechanical properties of the tendons which operate in
series with the muscle. A loss in tendon stiffness with age,
for example, would reduce the rate of force development
caused by skeletal muscle contraction, whereas increased
tendon stiffness with age would tend to counteract the age-
related decrease in skeletal muscle contractile function.
Animal studies of age effects on tendon mechanical
properties have yielded variable results, with some studies
showing increased stiffness with age [58], while other
studies have shown decreased stiffness with age [59, 60] or
little to no effect of age on tendon stiffness [61]. Narici et
al. have pointed out that some of this variability may be
attributable to differences in the age range between animal
groups as well as due to measurement artifacts associated
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with clamping of the excised tendons [62]. Human studies
of tendon properties have until recently been hindered by
requirements for cadaver donors and have been somewhat
scarce. To study tendon properties in vivo, a technique has
been developed based on longitudinal measurement of
tendon deformation by imaging ultrasound during an
isometric muscle contraction [63]. Initial studies using this
technique compared young and elderly groups, observing
that tendons from older subjects were on the order of 15%
more compliant [62]. The observation that the tendons from
the young and older subjects had approximately similar
dimensions supported the idea that the observed differences
could be attributed to differences in mechanical properties. In
addition to the observation that older tendons have lower
stiffness than tendons from younger subjects, there is also
evidence that tendon stiffness can be increased through exercise
training [64]. The ability to increase the stiffness of tendons
would improve mobility by allowing for faster generation of
force on bone, reducing the power and metabolic requirements
on skeletal muscle tissue. Narici et al. have presented excellent
reviews of the literature on age-related changes in human
tendon mechanical properties [62, 65].
Clinical manifestations of sarcopenia
With aging, multiple processes occurring within muscle
tissue, such as denervation, changes in the hormonal and
inflammatory environment, mitochondrial dysfunction, and
changes in the expression of regulatory factors affecting the
fate of satellite cells, combine to produce losses in the bulk
properties of muscle tissue such as muscle mass and
strength. Among the elderly, these changes may eventually
result in loss of mobility and independence and increased
risk of injury.
Loss of muscle power
Age-related loss of skeletal muscle contractile power,
which is essential to human motions such as rising from a
chair or climbing a flight of stairs, is one of the clinical
consequences most commonly linked with sarcopenia. The
decline in muscle power has been established in both
genders, under multiple loading conditions, in multiple
limbs, and in both cross-sectional and longitudinal studies
[17]. The most important anatomic sites for muscle function
measurement have primarily been in the lower body, as the
muscles in these sites are critical for daily function and
allow for closest comparison to biopsy data. Further, power
and strength losses in the lower limbs confer the largest risk
factors for falls and other sources of injury and disability
[66, 67]. Lower-limb power and strength are often
measured using knee extension and flexion. Measurements
can be isotonic, changing the length of the muscle fibers
against constant resistance, isokinetic, in which fibers are
shortened or lengthened at fixed velocity, or isometric, in
which fiber length remains constant in the presence of a
force greater than the muscle is capable of counteracting.
Isokinetic and isotonic measurements of knee extension and
flexion, in that they involve translating a weight along an
arc of motion within a given time interval, are measures of
muscle power (although they are mostly reported as joint
torques in feet pounds or Newton meters) whereas
isometric measurements involve purely the ability to
generate force. Because these loading conditions are more
relevant to human motion, most studies have reported
results of isokinetic and isotonic exercise. Table 1 summa-
rizes results of cross-sectional studies of lower-extremity
muscle function [68–73]. In cross-sectional studies com-
paring young normal subjects in the 20–40-year age range
to healthy elders in the 70–80-year age range, declines in
knee extensor torque and power have ranged from 20% to
40%, with greater losses in the 50% range reported for
individuals in their 1990s [74–78]. Over the lifetime, men
have inherently greater knee extensor power and torque
than women, but on a percentage basis, age-related losses
are similar between genders, with losses in men incurring
greater absolute losses because they start with higher
baseline values. Compared to the abundance of cross-
sectional studies, there are fewer longitudinal studies of
knee extensor properties with aging. Hughes et al.
examined a cohort of 52 elderly men and 68 women who
had been examined 10 years earlier, finding similar declines
in the knee extensors and flexors ranging from 12% to 18%
per decade [79]. Longitudinal studies of smaller cohorts
have shown variable results, with one study reporting losses
of roughly 3% per year in 23 men aged 73–86 at baseline
[80], and another study which reported no changes in
strength of either men or women over an 8-year follow-up
[81]. Cross-sectional studies of isometric measurements of
ankle plantar flexion have shown age-related declines
similar to those measured for knee extension torque and
power. Studies of age-related muscle strength in the upper
extremities show essentially similar results to the lower
extremities, with cross-sectional studies reporting declines
of 20–40% in measures such as hand-grip strength and
elbow extension torque between healthy younger subjects
and elderly subjects and longitudinal studies showing
yearly declines ranging from 1% to 5% [17].
Loss of skeletal muscle mass
Loss of skeletal muscle mass with age has been docu-
mented by lean body mass measurements with dual X-ray
absorptiometry (DXA) and with muscle cross-sectional
areas quantified by three-dimensional imaging methods
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such as X-ray computed tomography (CT) or with magnetic
resonance imaging (MRI). Leg lean tissue mass by DXA, a
marker for skeletal muscle mass, decreases by roughly 1%
per year in longitudinal studies [17], a value roughly
threefold smaller than the loss of skeletal muscle strength.
Studies which assess muscle mass through CSA measure-
ment have found that CSA decreases by roughly 40%
between 20 and 60 years, with the reported amount varying
with imaging technique, skeletal site, and gender [9, 16].
Measurements of the CSA of the quadriceps muscle using
CT have shown decrements of around 25–35% between
older subjects and young normal controls [82]. Large cross-
sectional studies including both older men and women have
found that men, on average, have larger muscle mass and
cross-sectional area values than women but that the largest
cross-sectional age-related changes occurred in men. This
potential gender difference in age-related loss of muscle
mass may reflect differences in the pattern of age-related
changes in testosterone, growth hormone, and IGF-1 [17].
Risk factors conferred by decrements in muscle power
and mass
Prospective cohort studies have demonstrated the associa-
tion of age-related loss of muscle strength and mass with
adverse clinical outcomes in the older population, including
falls, mobility limitations, incident disability, and fractures
[66, 67, 83]. Moreland et al. have carried out a meta-
analysis summarizing the relation of upper- and lower-body
weakness to falls [67]. Measures of lower-body weakness,
defined as increased chair stand time and reduced knee
extension strength, have been correlated to incidence of any
fall with odds ratios ranging from 1.2 to 2.5, to injurious
falls with odds ratios around 1.5, and to recurrent falls with
much higher odds ratios, ranging from 2.2 to 9.9. Upper-
body weakness, which is typically assessed using hand-grip
strength or manual muscle testing, is also correlated to fall
incidence, with odds ratios for incident falls ranging from
1.2 to 2.3 and for recurrent falls with odds ratios of 1.4–1.7.
Clearly, lower-extremity weakness is a better predictor of
falls than weakness of the upper body. Other studies have
explored the mechanisms by which impaired muscle
strength relates to falls by analyzing the effect of muscle
strength in single-step recovery from a forward fall [84–
87]. This may be simulated by leaning subjects forward and
then releasing them, measuring muscle activation, joint
kinetics, and other characteristics as the subjects step
forward after release. Multiple studies have found that
older individuals have discernible differences in these
measurements. Thelen et al. compared muscle activities in
young and elderly subjects and found that the latter showed
delays in activating the hip flexors and knee extensors
during the period in which the stepping leg is swung into
position [84, 85]. Wojcik et al. found that elderly adults
generate lower hip flexion and extension torques than
young adults during single-step recoveries after being
placed at a forward lean angle [86, 87]. Thus, there is
evidence that reduced strength of the hip and other lower-
leg muscles, in addition to impaired neuromuscular activa-
tion, may be implicated in poor recovery from falls. In
addition to falls, muscle weakness and reduced muscle
mass have been associated with incident disability. The
Health, Aging, and Body Composition Study investigators
carried out studies of body composition, muscle strength,
and other risk factors on incident mobility limitation,
defined as inability to walk a quarter mile or climb a flight
of ten stairs. Visser et al. observed that low-thigh muscle
CSA measured at baseline resulted in a 45% and 34%
increased risk of mobility limitations 5 years later in men
and women, respectively [88]. For low-knee extensor
power and torque, the risk of incident mobility limitation
was even higher, at 66% and 69% for men and women,
respectively [88]. The same study found that men and
women in the lowest quartile of thigh muscle cross-
sectional area and leg muscle mass had a 30–40% increase
of risk for the inability to carry out the activities of daily
living. For major disability, which includes inability to
carry out activities of daily living, inability to walk a
Table 1 Age-related changes in muscle power and muscle strength
Study Gender Measurement/joint/movement Age range (years) Study design Changes with aginga
Dean et al. 2004 [73] F IK/hip/FLX, EXT 21–82 CS ↓22–33%
Johnson et al. 2004 [72] F IK, IM/hip/AD, AB 21–91 CS ↓24–34% IK, ↓44–56% IM
Kubo et al. 2007 [71] M IM/ankle/PF 20–77 CS ↓40%
Morse et al. 2005 [70] M IM/ankle/PF 25.3±3.5–73.8±3.5 CS ↓47%
Petrella et al. 2005 [69] M, F IT/knee/EXT 20–75 CS ↓41–137%
Lanza et al. 2003 [68] M IT, IM/knee, ankle/EXT, DF 20–85 CS ↓26–32%
K isokinetic, IM isometric, IT isotonic, FLX flexion, EXT extension, AD adduction, AB abduction, PF plantar flexion; DF dorsiflexion, CS cross-
sectional
a Expressed as percent change with aging
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quarter mile, or climb ten steps, low-thigh CSA increased
risk by 40% whereas low-knee extensor strength resulted in
over a doubling of the risk. These subjects were also
followed up for incident hospitalizations, and low-thigh
CSA and muscle strength showed a similar predictive
power for this outcome. Thigh muscle cross-sectional area
and knee extension torque have also been shown to
correlate to incident hip fracture in the Health ABC study
[89]. Lang et al. observed that knee extension torque and
low cross-sectional area individually resulted in increased
risk of incident hip fracture by 50–60%, independent of
bone mineral density (BMD).
The increased risk of mobility loss and injury resulting
from loss of muscle mass and power are part of a vicious
cycle which is amplified with age. In addition to reductions
in performance, the intermediate consequences of muscle
loss include reductions in metabolic rate and aerobic
capacity. The loss of power and endurance increase the
difficulties associated with procuring adequate nutrition and
increase the effort required to undertake exercise. The
combination of nutritional loss and reduced physical
activity levels results in further loss of muscle mass and
power, exacerbating the process of sarcopenia. The result-
ing decrements in power, endurance, and physical perfor-
mance, if unchecked, then lead to a loss of independence
which may or may not be preceded by injury or illness, for
example a fall and/or fracture.
Treatments for sarcopenia
Exercise
Many studies have documented that exercise provides
benefits extending across multiple physiological systems
in the aged population. Resistive training, also known as
weight or strength training, can be used to counteract age-
related muscle loss by increasing the number and cross-
sectional areas of skeletal muscle fibers. Increases of 11.4%
in midthigh muscle CSA and greater than 100% in knee
extensor torque were reported by Frontera et al. in a cohort
of elderly men who had undergone 12 weeks of high-
intensity resistance exercise training [90], with similar
changes observed in a subsequent study in women by
Charette and colleagues [91]. Moreover, resistance exercise
even has benefits when it is not routinely performed. A
recent study by Henwood and Taaffe documented that
resistive exercise can produce sustained increases in knee
extensor torque even after periods of deconditioning
following cessation of exercise [92]. The benefits of
resistive exercise have been shown to extend even to frail
populations. Increases of 3–9% in muscle CSA, doubling of
muscle strength, and improvement in functional perfor-
mance indices have been reported in nursing home
populations after bouts of progressive resistance training
[93, 94]. Resistive exercise has been shown to be well
tolerated in the elderly and is of value in the prevention of
falls and loss of mobility. The time and equipment require-
ments to undertake a program of resistive exercise are
modest, with sessions of 30 min, twice per week, using
either exercise machines or body weight and elastic bands.
Finally, resistive exercise has been shown to result in
improvement in a range of different clinical conditions
common in elderly people, including osteoporosis, osteoar-
thritis, heart disease, diabetes, and depression. A summary
of relevant literature on exercise and pharmacologic
intervention in the elderly is presented in Table 2.
Hormone replacement
In elderly men, epidemiologic studies generally support a
relationship between declines in testosterone levels with age
and loss of muscle strength and functional status [95].
Menopause and age-related reduction of estrogen levels in
Table 2 Studies examining various interventions for age-related muscle loss
Study Population Gender Age N Intervention Findings
Solerte et al. (2008) [149] S M, F 66–84 41 AA supp. ↑Lean mass, ↑IGF-1, ↓TNF-α
Trappe et al. (2000) [150] E M 74±2 7 RT ↑S; ↑MHC I
Trappe et al. (2001) [151] E F 74±2 7 RT ↑S
Slivka et al. (2008) [152] E M 80–86 6 RT ↑S, ↑CSA
Fiatarone et al. (1990) [93] E M 90±3 10 HIRT ↑S, ↑CSA
Kryger et al. (2007) [153] E M, F 85–97 11 RT ↑S, ↑CSA
Frontera et al. (2003) [154] E F 68–79 14 RT ↑S, ↑CSA
Wittert et al. (2003) [155] E M 60–86 76 TE ↔S, ↑CSA
S sarcopenia, E elderly, Myo-29 a myostatin inhibiting drug, AA Supp amino acid supplement, RT resistance training, HIRT high-intensity
resistance training, TE testosterone, S strength, CSA muscle cross-sectional area, IGF-1 insulin-like growth factor 1, TNF-α tumor necrosis factor
alpha, MHC I, myosin heavy chain type I isoform
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women may also impact muscle strength because estrogen
is converted to testosterone, which has an anabolic effect on
muscle protein synthesis. Further, both sex hormones may
suppress inflammatory cytokines that exert catabolic effects
on muscle. Thus, hormone replacement has always received
considerable interest as a therapy for sarcopenia. In women,
trials of estrogen and testosterone therapy have failed to
yield any meaningful increases of muscle strength [96].
Studies of testosterone replacement therapy in men has had
mixed results, depending on age of the subjects. Several
studies have shown that administration of testosterone in
hypogonadal younger men produced significant increases
in lean body mass and muscle strength [97–99]. Strength
increases ranged from 20% to 60% but tended to be smaller
than the increases produced by resistive exercise training.
Anabolic effects of testosterone therapy on older hypogo-
nadal men tend to be weaker, with most studies reporting
minimal changes in body composition and no increases in
muscle strength [96]. However, some studies have reported
moderate strength improvements ranging from 10% to
25%, but unlike the negative results, all of these trials
lacked control groups. However, it should be noted that
testosterone is administered to older men in much lower
doses than to younger men because of increased risk of
prostate cancer and other side effects [96].
Considerable interest has also been devoted to testing the
effect of GH on sarcopenia. Growth hormone exerts an
indirect anabolic effect on muscle by stimulating produc-
tion of IGF-1 in the liver. Levels of growth hormone are
systematically lower in the elderly, and thus it was
hypothesized that GH would be effective in combating
muscle loss in elderly subjects. However, most studies have
shown that GH treatment is ineffective in the elderly, both
from the standpoint of muscle mass and muscle strength.
The failure of GH treatment to augment muscle strength in
elderly subjects has led to other approaches, such as
treatment with growth-hormone-releasing hormone, which
was found to increase GH production and produce moderate
increases in muscle strength [96–100]. Additionally, others
have tried direct administration of IGF-1. By complexing
IGF-1 to its primary circulating binding protein IGFBP-3, it
is possible to significantly increase the IGF-1 dose while
eliminating the side effect of hypoglycemia that occurs with
IGF-1 alone [101]. Boonen et al. reported that administration
of IGF-1/IGFBP-3 to elderly women with recent hip fracture
was well tolerated and resulted in increased grip strength
[102].
Newer pharmacologic approaches
Among the newer approaches evolving towards treatment
of muscle wasting is inhibition of myostatin, which
counteracts the myogenic regulatory factors which promote
the differentiation and proliferation of myocytes. In animal
studies, myostatin blockade using experimental agents and
other approaches appears to produce increases in muscle
mass and strength in rodent models [103–105]. Another
approach involves administration of selective androgen
receptor modulators (SARMs). These nonsteroidal agents
target the androgen receptor, which is found in sexual
organs, skeletal muscle, and bone but have less of a
stimulative effect on prostate and other sexual organs,
making them a candidate for treatment of frailty in older
subjects. These agents have been shown to improve lean
body mass in rodent models [106] and are currently in early
clinical trials.
Skeletal muscle and bone strength
Maintenance of muscle mass and strength is critical for
preservation of physical activity in older age and important
for reducing the risks of falls and their most serious
consequence, skeletal fractures. However, muscles exert
powerful loads on the skeleton, and there is considerable
interest in reducing fracture risk by using exercise strategies
to increase or at least protect against loss of skeletal mass
and strength with age [107]. The use of exercise strategies
to strengthen the skeleton is based on the adaptive response
of bone to varying mechanical loads as described by Frost,
who proposed a homeostatic process governing the balance
between bone remodeling, modeling, and repair as a
function of varying strains imposed by inputs such as
impacts and muscle forces [108]. The relationship between
mechanical strains and skeletal tissue responses vary with
the skeletal site, but the “set points” that trigger remodeling
and modeling responses and thus the overall responsiveness
of bone tissue to mechanical loading are modulated by the
overall hormonal milieu.
A series of animal experiments have studied the relation-
ships between mechanical strain and bone geometry and
strength [109]. These studies have demonstrated the
responsiveness of skeletal tissue to dynamic changes in
mechanical loading and have shown the importance of the
timing as well as the magnitudes of applied loads [110].
Recent studies have also indicated that mechanical loading has
an effect on other properties of bone such as fatigue resistance
and second moment of inertia that are significantly larger than
effects on bone density and mass [111].
However, studies examining the effect of exercise
regimes on bone in elderly subjects have indicated
relatively modest effects. An excellent review of various
exercise strategies on bone health has been published by
Suominen [107]. Impact exercise such as walking and
aerobic training has a pronounced benefit on overall health,
and a small but positive effect on bone mass. However,
from an anabolic point of view, resistive exercise seems to
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exert more favorable effects for potential improvements of
bone strength. High-intensity and progressive trials of
resistance exercise have shown significant effects on
BMD at vertebral and hip sites. Studies in general have
shown that the exercise must be continued to maintain the
benefit that the additional gain is lost within a few years of
the program if the protocol is not continued.
Assessment of skeletal muscle using imaging
Imaging offers the potential for an anatomic site-specific
assessment of multiple targets related to skeletal muscle
physiology. Imaging has an important role in research
studies of sarcopenia etiology and response to intervention.
The primary imaging target in skeletal muscle mass
assessment is lean body mass assessment by DXA, which
involves use of standard clinical bone densitometers to
decompose nonbone tissue into lean and fat body mass
components. Measurements may be obtained of total body
lean and fat mass as well as regional measures in the central
and appendicular skeleton. As this is an extremely
widespread and well-known technology, which is commonly
used in clinical studies in both bone and muscle research, we
will refer the readers to several reviews that lay out the
technical considerations for DXA soft tissue assessment
[112–116].
CT imaging may be employed to quantify bulk charac-
teristics of muscle and body composition that are highly
related to muscle strength and to overall functional ability
in the elderly. In particular, CT imaging is widely used to
study muscle and fat in epidemiologic studies of body
composition. Typically, acquisitions have included single
cross sections at the L1/2 or L4/5 intervertebral space to
image body fat or volumetric measurements obtained in the
abdomen and in the thigh, usually relating to the midthigh
or to a bony landmark [23, 83, 88, 117–121]. As shown in
Fig. 4, the key variables quantified include the total muscle
CSA of the midthigh, the CSA values of the quadriceps and
hamstrings, the total CSA of subcutaneous fat, and the
attenuation coefficients of the total thigh muscle and the
hamstrings and quadriceps separately. The CSA values of
the total thigh muscle and quadriceps muscle are positively
associated with increasing knee extensor strength [118].
The CSA declines with age, as does the muscle strength,
and is smaller in females than in males [117–119]. Another
property of great interest to the study of sarcopenia is the
mean attenuation coefficient [23, 117–119], which is
computed within all of the muscle regions after a threshold
is applied to exclude depots of fat embedded within each
muscle group. In elderly subjects, the mean attenuation
coefficient, when calculated in this manner, has been shown
histologically to correspond to fat accumulation within and
between the muscle cells. The increasing fat infiltration into
the muscle with aging may be an important, if not central,
aspect of sarcopenia. Lower values of the mean thigh muscle
attenuation coefficient correspond to increasing fattiness of
muscle tissue. Decreasing thigh muscle attenuation is
correlated to decreasing muscle strength, a relationship
which is independent of the muscle CSA and the total
amount of adipose tissue in the thigh.
Measures of CSA and muscle attenuation assessed at
multiple skeletal sites are associated with indices of
functional capacity in elderly adults, including chair stand
and leg strength measurements which have been shown to
be strongly predictive of falls [83, 88, 121]. Several studies
based on the Health, Aging, and Body Composition Study,
a large NIH-funded population study, have related measures
of body composition derived by CT to indices of functional
ability and quality of life in the independently living
elderly. Visser et al. examined the relationship between
measures of thigh composition and lower-extremity perfor-
Fig. 4 CT acquisition through
midthigh. Location of axial sec-
tion is shown on localizer image
at the left, with corresponding
axial image in the middle and
segmentation into distinct tissue
compartments at the right.
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mance (LEP), assessed by two timed tests: a series of five
chair stands without use of arms and a 6-m walk [83].
Reduced thigh CSAwas associated with poorer LEP, as was
reduced thigh muscle attenuation coefficient, even after the
adjustment for muscle area. The attenuation coefficient of
thigh muscle is not only related to current physical
performance but is also related to incident functional
decline. Analyzing longitudinal data from the Health ABC
study, Visser et al. observed that low baseline values of
thigh muscle attenuation predicted incident mobility limi-
tation, defined as inability to walk one-quarter mile or
climb ten steps [88]. Reduced thigh muscle attenuation
coefficient is also associated with increased insulin resis-
tance and the presence of metabolic syndrome in the
elderly. Diabetes and other weight-related health conditions
are associated with poor vision, musculoskeletal pain, and
other conditions which are themselves indicators of
increased fall risk [23].
Magnetic resonance imaging
MRI is an imaging technique that is based on using radio
waves to excite protons in the presence of an external
magnetic field. The resonance frequency at which protons
maximally absorb the radioenergy is based on their local
chemical environment. Because musculoskeletal tissues are
rich in proton-containing molecules such as muscle proteins
and lipids, MRI is an inherently powerful tool at depicting
the anatomy of muscle tissues, particularly in the delinea-
tion of lean and adipose components of muscles. While
some investigators have used 3D MRI acquisitions to
determine lean tissue and intermuscular fat volumes in a
range of applications, the true advantage of MRI is the
ability to obtain spectroscopic data that can probe in vivo
the ATP-generating functions within skeletal muscle and
the storage of important nutrients such as lipid and
glycogen.
Proton magnetic resonance spectroscopy (1H-MRS) is a
technique that can differentiate lipids stored within adipo-
cytes (extramyocellular lipid, EMCL) from intramyocellu-
lar lipid (IMCL) stored as droplets on the border of the
myoplasm [122–127]. This differentiation is based on the
variance in resonance frequency between protons contained
in relatively cylindrical deposits of EMCL in adipocytes
and protons contained in IMCL deposits which are
spherical in shape. These resonances show up as different
peaks on the proton spectrum of skeletal muscle (Fig. 5).
Probing IMCL is of clinical importance because IMCL
stores represent lipid which borders mitochondria and
which represent an energy supply of free fatty acids for
oxidation. IMCL intensity determined by 1H-MRS has been
found to correlate with insulin resistance and obesity. The
risk of insulin resistance is known to increase with age, and
aging skeletal muscle is characterized by decreasing
oxidative capacity that may lead to increased IMCL.
MRS may also be used to detect resonances of 31P and
13C nuclei contained in ATP, ADP inorganic phosphate,
glycogen, and other chemical forms in skeletal muscle
cells, shedding important light on muscle metabolism. 31P-
MRS can be used to directly analyze relative abundances of
31P contained in compounds of interest to energetics of
skeletal muscle, including ATP, inorganic phosphate, and
phosphocreatine [128–134]. Based on these primary meas-
urements, it is also possible to use 31P-MRS to indirectly
Fig. 5 MRI image of calf at the right, with green and yellow boxes
indicating locations of spectroscopic acquisitions of the tibialis
anterior and soleus muscles, respectively. Proton spectroscopy studies
may be used to assess the relative amounts of intramyocellular and
extramyocellular lipid. At the right, a proton spectrum corresponding
to the soleus muscle shows 1H resonances associated with creatinine
(CR2 and CR3), water, extramyocellular lipid (EMCL), intramyocel-
lular lipid (IMCL), and trimethylamines (TMA)
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estimate the intracellular pH, as well as the free concen-
trations of ADP and Mg2+ ions. These measurements allow
the technique to be used to estimate rates of ATP synthesis
under ischemic (glycogenolytic) conditions or aerobic
(oxidative) conditions. Other applications in skeletal muscle
studies include estimates of the oxidative capacity of
skeletal muscle, as well as the proton efflux and buffer
capacity, which provide insight into the recovery of skeletal
muscle from exercise.
The wide chemical shift of the 13C resonance allows
13C-MRS to assess the relative abundances of a wide range
of molecules related to glycogen synthesis and glycogen-
olysis [129, 135–143]. Using the natural abundance (1.1%)
of 13C, it is possible to detect resonances of 13C in glycogen
and triglyceride. This allows for estimates of glycogen
turnover in skeletal muscle and for studies of insulin
resistance and type 2 diabetes. By administration of 13C
glucose, it is possible to enrich 13C, allowing for more
advanced determinations, such as examining glycogen
synthesis rate and quantifying organelle and mitochondrial
activity during the TCA cycle.
Positron emission tomography
Positron emission tomography (PET) is an imaging
technique which is employed to image the biodistribution
of a compound of interest labeled with a positron-emitting
atom, for example an 18F or 11C. The most commonly
employed PET imaging agent is 18F-fluorodeoxyglucose
(FDG), a glucose analog which is widely employed to
study glucose metabolism across multiple tissue types. 18F-
FDG penetrates the cell membrane and is phosphorylated to
FDG-6-phosphate and is no longer metabolized and thus is
trapped within the cell. It builds up in the cell in proportion
to the rate of glucose transport across the cell membrane
and also in relation to the activities of hexokinase and
glucose-6-phospotase within the cell. In skeletal muscle,
FDG imaging has been employed to study glucose
utilization. When used in conjunction with compartmental
modeling, this approach has been employed to dissect the
rate of glucose utilization in terms of the components of cell
membrane transport and phosphorylative activity in insulin
resistance associated with both obesity and diabetes [144,
145]. Another application of PET which is relevant to
skeletal muscle is the use of 11C-methyl-methionine to
estimate the rate of protein synthesis. This agent accumu-
lates in skeletal muscle as 11C-labeled protein, and the use
of this methylated agent has advantages over radiolabeled
leucine in that the latter accumulates in the blood as 11C-
labeled CO2. Fischmann and others have validated this
technique against skeletal muscle biopsy and have used it to
outline the rate of skeletal muscle protein synthesis in
healthy young volunteers [146–148].
Conclusions
Sarcopenia represents a set of outcomes, including the
primary outcomes of loss of skeletal muscle strength and
endurance, and secondary outcomes which include loss of
mobility and increased risk of disability and mortality. The
bulk changes of muscle tissue which lead to these outcomes
result from multiple processes occurring at the cellular
level. These processes impact the performance of muscle by
reducing the number of fibers and the performance of
individual fibers. Age-related loss of motor neurons results
in denervation of entire fibers, with a concomitant adaptive
process that recruits some but not all of these of these fibers
into surviving motor units. Changes in the hormonal and
inflammatory milieu result in impairment of protein
synthesis and increased protein degradation. Buildup or
ROS may result in mitochondrial dysfunction which
impairs muscle respiration and may result in fiber deterio-
ration through loss of myonuclei. Alterations in expression
of myogenic regulatory factors may impair the ability of
aged muscle to repair damage. Fortunately, despite this
wide range of deleterious age-related changes, there are
promising interventions. Multiple studies have shown that
resistive exercise among the elderly of both genders can
result in substantial improvements in muscle strength and in
overall functional status, where increases in muscle strength
indices can exceed 50–100%. For subjects who cannot
tolerate or are unwilling to undertake exercise, pharmaco-
logic interventions, such as GH or IGF-1 interventions, are
under investigation. These have had mixed results, and
newer approaches, such as myostatin inhibition and
selective androgen receptor modulators, are also in the
early stages of investigation. Noninvasive imaging
approaches such as CT, MRI, and PET are showing promise
as clinical tools that may yield important basic information
regarding the mechanisms of sarcopenia and the modes of
action of multiple interventions.
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